NVDA Bull Case Revisited: Why the 18% Consolidation Was Multiple Compression, Not Deterioration

## The Consolidation Context

NVDA pulled back 18% from its high over six weeks. In that period:

- No negative fundamental news - No guidance revision - No competitive development that changes the thesis - One export control update (manageable, not thesis-breaking)

The pullback was multiple compression in response to broader market risk-off, not fundamental deterioration. When the stock is down 18% and the thesis is intact, that is a buying opportunity. I re-entered my full position at $118.40.

This piece documents the updated thesis and why I have not lowered the target.

## Original Thesis vs Updated Reality

**Original thesis (published at $134):** - Blackwell demand is capacity-constrained through at least H1 FY2026 - Gross margins expand 300–400bps with Blackwell ASP premium - Sovereign AI demand is a new, not-modeled TAM vector - Target: $185 in 12 months

**Post-pullback update:** All four pillars are intact. If anything, the channel check data from the consolidation period is more constructive than at the time of the original thesis:

| Pillar | Original signal | Current signal | Delta | |--------|----------------|---------------|-------| | Blackwell demand | Constrained | Still constrained | Unchanged | | GM expansion | H200 ASP +35% | B200 data confirming +40–45% | More positive | | Sovereign AI | Emerging | UAE/Saudi orders confirmed in earnings | Confirmed | | TAM | $150B data center 2025 | Raised to $170B+ by consensus | Upgraded |

## What the Bears Are Saying (and Why I Disagree)

**Bear argument 1: "AMD MI300X is taking share"** MI300X is gaining in inference workloads. This is true. But training — where NVDA has 85%+ share — is where the revenue is. Inference is growing but is a fraction of training revenue in dollar terms. The competitive threat is real but overstated relative to the revenue line.

**Bear argument 2: "China export controls are an existential risk"** H20 restrictions reduced China TAM by ~8%. This has already happened. The question is whether further restrictions arrive. My base case: no material escalation in the next 12 months given the diplomatic environment. The risk is real; the probability of the extreme scenario is low.

**Bear argument 3: "The valuation is too high at 35x"** 35x forward earnings on a company growing revenue 200%+ is not obviously expensive. The relevant comparison is not absolute P/E but P/E relative to growth (PEG ratio). At 35x with 200% revenue growth, the PEG is 0.17 — one of the cheapest in the S&P 500 on that metric.

## Position Update

- Re-entered at $118.40 on the 18% pullback from $145 high - Position size: Full (same as original entry) - Stop: Weekly close below $110 (8% below re-entry) - Target: $185 unchanged — represents 57% upside from re-entry

The risk/reward from re-entry is more attractive than the original entry. Same target, 17% lower cost basis.

## What Would Change My Mind

1. A gross margin miss (below 73%) for two consecutive quarters 2. Blackwell lead time data showing demand destruction (not supply loosening) 3. A hyperscaler capex guidance cut of >10% aggregate 4. Regulatory action that extends restrictions beyond China to other geographies

None of these have occurred. Until they do, the thesis stands.